Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260205 | 1.00 | CDK2 (0.43) | CDK2CCNA2CCNA1HDAC1GLS | |
| SCHEMBL5260601 | 0.88 | CCNA2 (0.45) | CDK2CCNA2CCNA1HDAC1KMT2A | |
| SCHEMBL5260598 | 0.88 | CCNA2 (0.45) | CDK2CCNA2CCNA1HDAC1KMT2A | |
| SCHEMBL5261374 | 0.88 | CCNA2 (0.34) | CDK2CCNA2CCNA1GLSKMT2A | |
| SCHEMBL5261372 | 0.88 | CCNA2 (0.34) | CDK2CCNA2CCNA1GLSKMT2A | |
| SCHEMBL5259557 | 0.86 | MEN1 (0.36) | CDK2CCNA2CCNA1KMT2AMEN1 | |
| SCHEMBL5259559 | 0.86 | MEN1 (0.36) | CDK2CCNA2CCNA1KMT2AMEN1 | |
| SCHEMBL5263164 | 0.85 | NPY5R (0.42) | CDK2CCNA2CCNA1GLSKMT2A | |
| SCHEMBL5263161 | 0.85 | NPY5R (0.42) | CDK2CCNA2CCNA1GLSKMT2A | |
| SCHEMBL5263514 | 0.84 | WNT3A (0.37) | HDAC1KMT2AWNT3AHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309590-B1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-09-19 | — | — | EP | claimed |
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN (IT) | 2003-01-02 | — | — | US | claimed |
| US-6335342-B1 | 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-01-01 | — | — | US | claimed |
| EP-1309590-B1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-09-19 | — | — | EP | disclosed |
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN (IT) | 2003-01-02 | — | — | US | disclosed |
| US-6486322-B1 | Azaindole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2002-11-26 | — | — | US | disclosed |
| US-6335342-B1 | 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | FFAR4, AZI2, CNKSR1 | CDK2 316/4885CCNA2 315/4885CCNA1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.